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• How to develop the new radiopharmaceutical 
stressing and keeping the pharmaceutical aspects
of radiopharmaceuticals
• How to implement the new radiopharmaceutical in 
the nuclear medicine clinical practice and in the 
methods of quality assurance
• Selection of pharmaceutical based on organ-specific question.
• Labeling of pharmaceutical with radioactive isotopes.
• Radiopharmaceuticals should not disturb the process under 
investigation
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Radiopharmacy is a specialty area of
pharmacy practice dedicated to the
compounding and dispensing of
radioactive materials for use in
nuclear medicine procedures.”
- Ready-to-use licensed radiopharmaceuticals: prepared and 
delivered to hospital by RP-manufacturer
- Radiopharmaceuticals prepared just before use in the 
nuclear medicine department using licensed labelling kits 
and eluate of a licensed technetium-99m generator or 
licensed precursor radionuclide
- Radiopharmaceuticals synthesized on site in (mostly) 
several steps starting from raw materials and (in house) 
cyclotron produced radionuclide (most radiopharmaceuticals 
for positron emission tomography (PET)
- radiolabelled patient’s autologous blood cells
- Most radiopharmaceuticals are used for 
medical diagnosis
- Contain only small amounts of the  active 
substances with a radionuclide attached to 
them to allow scintigraphic imaging or 
measurement of biodistribution
- Not often show any measurable 
pharmacodynamic effect
- Radiation is a general property of all 
radiopharmaceuticals, and give to the patient 
an inevitable radiation dose
- In therapeutic radiopharmaceuticals, the 
radiation effect is the wanted property
- Evaluation of the safety and efficacy should 
include radiopharmaceutical and radiation 
hygiene aspects and radiation dosimetry in 
addition to general parameters.
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1. Qualitative and quantitative specifics of the constituents and development pharmaceutics
2. Description of method of preparation (obtaining and maintaining sterility during 
manufacture (preparation and assembly) - validation of processes
3. Control of starting materials
4. Control tests on the finished product
5. Stability tests
6. Toxicological and Pharmacological Tests - toxicity may be associated with a radiation dose
7. Single dose/repeated dose toxicity
8. Examination of reproductive function and foetal toxicity
9. Mutagenic potential / Carcinogenic potential
10. Pharmacodynamics / Pharmacokinetics
Positron emission tomography (PET) is a unique diagnostic modality in that
it provides images of the human body's basic biochemical functioning.
PET radiopharmaceuticals are unique among radiopharmaceuticals
because of their short physical half-lives, ranging from a few seconds to
several hours.
- short physical half-lives of PET radioisotopes
- prolonged preparation time significantly erodes the useful clinical life of PET 
radiopharmaceuticals
- must be administered to patients shortly after production
- the quantities of active ingredients contained in each lot of a PET 
radiopharmaceuticals generally vary from microgram to nanogram amounts
- PET radiopharmaceuticalsdo are not usually in a general drug distribution
chain (the entire lot/one vial) is usually distributed directly from the PET 
facility to a single nuclear medicine department to a nuclear pharmacy for
dispensing. 
Established procedures and current good
manufacturing practice (CGMP) 
requirements for PET 
radiopharmaceuticals conflict with
differentiation between manufacturing
and compounding. 
• They have already all documentation…
• They have already got wipe tests and calibrations 
and phantoms and surveys…
• They have already got MDs, specialy in Nuclear 
medicine and PhDs…
“They are using low risk diagnostic doses anyway…”
“Radiopharmaceuticals don’t have side effects…”
“Patients get images which can help their diagnosis…”
 Good starting point:
Wrong consideration:
1. Clinical pharmacology 
Pharmacodynamics / Pharmacokinetics
2. Clinical trials - to prove their safety in use and 
their value as diagnostic or therapeutic agents
- Diagnostic/therapeutic efficacy
- Adverse reactions
- Interactions
- Dosage
• All regulations and guidance for clinical trials 
exist to protect human subjects
• Fraud and unethical practices still occur today
• The appearance of fraud or unethical behavior 
can be detrimental to the investigator and 
sponsor
• Sponsors expect nuclear medicine investigators 
and study coordinators to be knowledgeable 
about the regulations and guidance documents
La belleza perece en la vida pero es
inmortal en el arte.
Leonardo Da Vinci
